DRW Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

DRW Securities’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-420	Closed	-$220K	–	1283
2026 Q1	$220K	Buy	+420	New	+$201K	﹤0.01%	1062

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DRW Securities's MDGL Position: Q2 2026 in Review

DRW Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 420 shares — an estimated $220K sold.

DRW Securities first reported a position in MDGL in Q1 2026 and held it in 1 quarter. The position peaked at $220K in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

DRW Securities reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 420 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $220K.
DRW Securities first reported a position in Madrigal Pharmaceuticals in Q1 2026 and held it in 1 quarter.
DRW Securities's Madrigal Pharmaceuticals position peaked at $220K in Q1 2026.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.